Epidemiological and biological plausibility studies support a cause-and-effect relationship
between increased levels of physical activity or cardiorespiratory fitness and reduced …

Aspirin is currently the most widely used drug worldwide, and has been clearly one of the
most important pharmacological achievements of the twentieth century. Historians of …

Background More information is needed about the long-term effects of low-dose aspirin (≤
160 mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal …

Background: Long-term outcomes of antiplatelet monotherapy in patients who receive
percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal …

In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …

The success of trials that have shown net clinical benefits of antithrombotic drugs as well as
the increasing prevalence of cardiovascular diseases in an ageing population have led to …

Evidence on aspirin and cancer comes from two main sources:(1) the effect of aspirin upon
biological mechanisms in cancer, and (2) clinical studies of patients with cancer, some of …

High platelet reactivity and gastric mucosal injury after aspirin (ASA) treatment are
associated with poor compliance and an increased risk of cardiovascular events. Panax …

Four decades have passed since the first trial suggesting the efficacy of aspirin in the
secondary prevention of myocardial infarction. Further trials, collectively summarized by the …

Background: Dual antiplatelet therapy (DAPT) with aspirin as a background therapy has
become the standard care after percutaneous coronary intervention. However, some …